Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has priced a public offering of an aggregate of approximately 7.1 million shares of common stock at a price to the public of $0.50 per share. Investors will also receive warrants to purchase up to an aggregate of approximately 3.55 million shares of common stock with an exercise price of $0.50 per share. The warrants have a term of exercise of five years and are exercisable upon Apricus' receipt of shareholder approval to increase its number of authorized shares from 30 million shares to 60 million shares. The offering is expected to close on or about April 2, 2018, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
The aggregate gross proceeds of the offering are anticipated to be approximately $3.55 million. After deducting the placement agent's fees and other estimated offering expenses payable by Apricus, the net proceeds of the offering are anticipated to be approximately $2.9 million. Apricus intends to use the net proceeds from the offering for working capital and general corporate purposes.
The shares and warrants are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-221285), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on December 7, 2017. A preliminary prospectus supplement describing the terms of the offering was filed with the SEC on March 27, 2018 and March 28, 2018, and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or emailing email@example.com or at the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus' expectations on the completion, timing and size of the offering and the expected gross proceeds from the offering and the anticipated use of proceeds therefrom. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering; and other risks and uncertainties inherent in Apricus' business, including those described in the Apricus' periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.
CONTACT: Matthew Beck
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Eurotunnel entrusts the mid-life renovation of its Passenger Shuttles to Bombardier Transportation20.3.2019 08:30:00 CET | Pressemelding
BERLIN, March 20, 2019 (GLOBE NEWSWIRE) -- As part of the 2018-2026 mid-life programme, Eurotunnel is signing a contract with Bombardier Transportation to renovate nine “PAX” Shuttles. Composed in total of 254 wagons, each 800-meter long shuttle is made up for passengers’ vehicles with passengers remaining in their vehicles during for the 35-minute Channel crossing. In the 25-year period since the opening of the Channel Tunnel, these Shuttles have each travelled an average of 300 round trips per month and have enabled over 236 million passengers to travel very comfortably between France and Great-Britain. The contract is valued at €150 million ($171 million) over a period of 7 years. Deliveries of the newly refurbished Shuttles will start in mid-2022 and continue until mid-2026. Teams from Bombardier France and Belgium1 originally designed and built these unique vehicles in the 90’s and launched Bombardier’s activities in France. This year, the company celebrates 30 years since its est
Standard Lithium Engages WorleyParsons’ Advisian for Preliminary Economic Assessment of Its Southern Arkansas Project20.3.2019 08:01:00 CET | Pressemelding
VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to announce that it has engaged Advisian, the consulting arm of WorleyParsons Canada Services Ltd (WorleyParsons) to complete a Preliminary Economic Assessment (PEA) of its flagship 150,000 acre project in the south-central region of Arkansas, USA. Advisian is part of WorleyParsons, one of the world’s largest engineering and project delivery firms, servicing the global resource, energy, and infrastructure markets with 26,910 personnel across 115 offices in 42 countries around the globe. Advisian and WorleyParsons have carried out many lithium studies for brine and produced-water projects in North and South America for a range of operating and development-stage clients. WorleyParsons also has extensive experience in planning, developing and building chemical plants in the US Gulf Coast region. Standard Lithium has e
ISSI HyperFlash™ memory has successfully been designed into the NXP i.MX RT106A MCU-based solution for AVS (Alexa Voice Service)19.3.2019 21:30:00 CET | Pressemelding
MILPITAS, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Integrated Silicon Solution, Inc. a leader in advanced memory solutions, today announced the adoption of HyperFlash™ memory IS26KL256S-DABLI00 (256Mb 3.3V BGA package) with NXP’s i.MX RT106A MCU based solution for AVS (Alexa Voice Service). The Alexa Voice Service (AVS) is a virtual assistant developed by Amazon that provides cloud-based automatic speech recognition (ASR) and natural language understanding (NLU) to provide information, media playback, communication and smart device control capabilities to consumers. HyperFlash™ memory based on the HyperBus™ technology dramatically improves memory performance while reducing pin count and board space, essential for NXP’s implementation to save BOM cost without compromising performance to do XIP (execute-in-place) operations. “NXP is an important partner for us. We are very glad that NXP adopted our HyperFlash™ solution. HyperFlash™ fits nicely in the application to meet the increasingl
NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®19.3.2019 21:05:00 CET | Pressemelding
The combined company was named NLS Pharmaceutics Ltd (NLS) STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive disorders and impairments, today announced the closing of the merger of NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, effective immediately. The combined company was named “NLS Pharmaceutics Ltd.” The sideways merger brings together the global operations and assets of the three companies in order to streamline the development of Nolazol®, a controlled release formulation of mazindol that is currently being developed as a non-amphetamine DEA schedule C-4 treatment option for ADHD and narcolepsy, as well as a promising pipeline of early to late-stage compounds focusing on ADHD, sleep disorder and other rare diseases. Leading the combined company as Chief Executive Officer is Alex Zwyer, who served as c
INVNT Recognised for Xero and TEDxSydney Work at The Event Marketing Awards 201919.3.2019 14:30:00 CET | Pressemelding
HONG KONG, March 19, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, in partnership with Xero has received the Best Corporate Event Gold Award at the prestigious Event Marketing Awards 2019 organised by Campaign Asia-Pacific and CEI, for its production, management and design of Xerocon Brisbane 2018 – Australasia’s largest technology conference for the accounting industry. During the ceremony, which was held at the Eaton Club in Hong Kong on Tuesday evening local time, INVNT was also recognised with the Best Sustainability Bronze Award alongside client TEDxSydney, for the production of the not-for-profit organisation’s flagship event in 2018, which was themed around the concept of HumanKind and saw the agency devise and implement a series of environmentally friendly initiatives. Now in their fourth year, the Event Marketing Awards organised by Campaign Asia-Pacific and CEI recognise best practice in the creation, planning, production and management of innova
Crocus Technology Unveils its 2nd Generation TMR Linear Sensor with Unparalleled Temperature Stability19.3.2019 13:00:00 CET | Pressemelding
The CT100 is a unique TMR magnetic sensor with industry-leading performance SANTA CLARA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Crocus Technology Inc., a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces the CT100 device, an advanced, high-performance linear (1D) magnetic sensor based on Crocus’ patented and unique TMR-based technology. The CT100 has best-in-class performance across a wide temperature range coupled with an extremely low linearity error, low hysteresis, and low noise which enables it to address many consumer, industrial and automotive applications and markets. The CT100 outperforms competitors’ xMR or Hall-based linear magnetic sensor technology available today in terms of performance, deviation over temperature, current consumption, and overall robustness. The CT100 does not require any expensive flux guides or concentrators, chopping circuits or set/reset pulses and operates over a wide magnetic field range. Crocus’s revolutio